Administration of resveratrol to prevent or treat restenosis following coronary intervention
AssigneePharmascience Inc.
InventorDavid William Goodman
Life of this patent
Estimating the term…
Abstract
A method for preventing or treating restenosis and for preventing the recurrence or progression of coronary heart disease is provided. The method involves administration of a selected active agent to a patient following coronary intervention, e.g., coronary artery bypass surgery, endarterectomy, heart transplantation, heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting. The active agent comprises cis-resveratrol, trans-resveratrol, a mixture thereof, or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof. Administration may be oral, parenteral, or the like. Pharmaceutical compositions for use in conjunction with the therapeutic method are also provided.
Claims18
A pharmaceutical composition for preventing or treating restenosis in an individual following coronary intervention, comprising:
- a unit dosage of an active agent selected from the group consisting of resveratrol and pharmacologically acceptable salts, esters, amides, and mono- or di-saccharide conjugates thereof;
- and a pharmacologically acceptable carrier, wherein the unit dosage of active agent is effective to prevent or treat restenosis in an individual following coronary intervention.
Dependencies are inferred from the claim text.